SEC Tracker
Get the app

Estrella Immunopharma ESLA

Estrella Immunopharma appoints new CEO

Item 5.02 Executive or director change, Item 8.01 Other events

Form
8-K
Filed
Importance
Major
  1. Cynthia Pussinen appointed as CEO and Board Chair effective Oct 25, 2026.
  2. Dr. Cheng Liu becomes Chief Scientific Officer, retaining President role.
  3. Pussinen's employment agreement includes $250k base salary and equity awards.
  4. Amendments adjust Dr. Liu and CFO's compensation to match new CEO's terms.

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Estrella Immunopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Fibrogen FGEN public float $21M, Jun 30, 2025
  2. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  3. Imunon IMNN public float $21M, Jun 30, 2025
  4. Lunai Bioworks LNAI public float $21M, Dec 31, 2025
  5. Dare Bioscience DARE public float $21M, Jun 30, 2025